AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1 (original). A method for preventing or treating toxicity due to a pyrimidine nucleoside analog comprising administering to an animal a pharmaceutically effective amount of an acylated derivative of a non-methylated pyrimidine nucleoside.

2 (original). A method as in claim 1 wherein said acylated derivative of a non-methylated pyrimidine nucleoside is an acyl derivative of uridine, cytidine, deoxycytidine, or deoxyuridine.

3 (original). A method as in claim 1 wherein said toxicity is damage to hematopoietic tissue.

4 (original). A method as in claim 1 wherein said toxicity is damage to mucosal tissues.

5 (original). A method as in claim 1 wherein said pyrimidine nucleoside analog is an antineoplastic agent.

6 (original). A method as in claim 1 wherein said pyrimidine nucleoside analog is an antiviral agent.

7 (original). A method as in claim 1 wherein said pyrimidine nucleoside analog is an antimalarial agent.

8 (original). A method as in claim 1 wherein said pyrimidine nucleoside analog is a cytotoxic analog of uridine.

9 (original). A method as in claim 1 wherein said pyrimidine nucleoside analog is a cytotoxic analog of cytidine.

10 (original). A method as in claim 1 wherein said pyrimidine nucleoside analog is an inhibitor of pyrimidine nucleotide biosynthesis.

11 (previously presented). A method as in claim 1 wherein said pyrimidine nucleoside analog is selected from the group consisting of 5-fluorouracil (5-FU), 5-FU prodrugs including Tegafur and 5'-deoxy-5-fluorouridine, 5-fluorouridine, 2'-deoxy-5-fluorouridine, prodrug derivatives of 5-fluorouridine or 2'-deoxy-5-fluorouridine, fluorocytosine, trifluoromethyl-2 '-deoxyuridine, arabinosyl cytosine, prodrugs of arabinosyl cytosine, cyclocytidine, 5-aza-2'-deoxycytidine, arabinosyl 5-azacytosine, 6-azacytidine, N-phosphonoacetyl-L-aspartic acid (PALA), pyrazofurin, 6-azauridine, azaribine, thymidine, and 3-deazauridine.

12 (original). A method as in claim 1 wherein said pyrimidine nucleoside analog is selected from the group consisting of AZT, dideoxycytidine, 5-ethyl-2'-deoxyuridine, 5-iodo-2 '-deoxyuridine, 5-bromo-2 '-deoxyuridine, 5- methylamino-2 '-deoxyuridine, arabinosyluracil, dideoxyuridine and (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine.

13 (original). A method as in claim 1 wherein said pyrimidine nucleoside analog is 5-fluoroorotate.

14 (original). A method as in claim 1 wherein said acylated derivative of a non-methylated pyrimidine nucleoside is triacetyluridine.

15 (original). A method as in claim 1 wherein said acyl derivative of a non-methylated pyrimidine nucleoside is ethoxycarbonyluridine.

16 (original). A method as in claim 1 wherein said acylated derivative of a non-methylated pyrimidine nucleoside is triacetylcytidine.

17 (original). A method as in claim 1 wherein said acylated derivative of a non-methylated pyrimidine nucleoside is diacetyldeoxycytidine.

18 (original). A method as in claim 1 wherein said acylated derivative of a non—methylated pyrimidine nucleoside is an acylated derivative of uridine, deoxyuridine, or cytidine, and said administering step also includes administering an inhibitor of uridine phosphorylase.

19 (original). A method as in claim 18 wherein said inhibitor of uridine phosphorylase is selected from the group consisting of benzylacyclouridine, benzyloxybenzylacyclo-uridine, aminomethyl-benzylacyclouridine, aminomethyl-

benzyloxybenzylacyclo-uridine, hydroxymethyl-benzylacyclouridine, and hydroxymethyl-benzyloxybenzylacyclouridine, 2,2'-anhydro-5-ethyluridine, 5-benzyl barbiturate, 5-benzyloxybenzyl barbiturate, 5-benzyloxybenzyl-1-[(1-hydroxy-2-ethoxy)methyl] barbiturate, 5-benzyloxybenzylacetyl-1-[(l-hydroxy-2-ethoxy)methyl] barbiturate, and 5-methoxybenzylacetylacyclobarbiturate.

20 (original). A method as in claim 1 wherein said acylated derivative of a non-methylated pyrimidine nucleoside is an acylated derivative of cytidine or deoxycytidine, and said administering step also includes administering an inhibitor of cytidine deaminase.

21 (original). A method as in claim 20 wherein said inhibitor of cytidine deaminase is selected from the group consisting of tetrahydrouridine or tetrahydro-2'-deoxyuridine.

22 (original). A method as in claim 1 wherein said acylated derivative of a non-methylated pyrimidine nucleoside is an acylated derivative of uridine, cytidine or deoxycytidine, and said administering step also includes administering an inhibitor of nucleoside transport.

23 (original). A method as in claim 22 wherein said inhibitor of nucleoside transport is selected from the group consisting of dipyridamole, probenicid, lidoflazine or nitrobenzylthioinosine.

24 (original). A method as in claim 1 wherein said administering step also includes administering an agent which enhances hematopoiesis.

25 (original). A method as in claim 1 wherein said administering step also includes administering a compound capable of enhancing the uptake and phosphorylation of nucleosides into cells.